Products (none as of 2012) Founded 1995 | Website www.intarcia.com Type Privately held company | |
 | ||
Industry pharmaceutical industry Key people Kurt C. Graves (Chairman/President/CEO)
James M. Ahlers (Principal Finance and Accounting Officer)
Michelle A. Baron M.D. (Chief Medical Officer) CEO Kurt C. Graves (Apr 2012–) Headquarters Boston, Massachusetts, United States | ||
Intarcia therapeutics ceo disrupting diabetes mad money cnbc
Intarcia Therapeutics is an American pharmaceutical company based in Hayward, California and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In April 2012, the company announced its intention to relocate its headquarters to the Boston-area.
Contents
- Intarcia therapeutics ceo disrupting diabetes mad money cnbc
- Intarcia therapeutics ceo holy grail of disease treatment mad money cnbc
- Investors
- References
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO.
As of 2012, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA-650, the therapeutic consists of exenatide delivered via its DUROS system, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".
Intarcia therapeutics ceo holy grail of disease treatment mad money cnbc
Investors
In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. Other Investors include Greenspring Associates , Alta Partners and Granite Venture Partners.